Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Anthera Pharmaceuticals (ANTH) Stock Price
News stories about Anthera Pharmaceuticals (NASDAQ:ANTH) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.9469753547896 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Anthera Pharma (ANTH) Receives Nasdaq Listing Determination Notice, Plans Appeal (streetinsider.com)
- Jefferies Group Equities Analysts Lift Earnings Estimates for Anthera Pharmaceuticals, Inc. (ANTH) (americanbankingnews.com)
- Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal – GlobeNewswire (press release) (globenewswire.com)
- Why Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Jumped – Stock News Union (blog) (stocknewsunion.com)
ANTH has been the topic of a number of research reports. Jefferies Group LLC restated a “hold” rating and issued a $1.75 price objective (down previously from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th. Zacks Investment Research lowered Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $5.11.
Shares of Anthera Pharmaceuticals (ANTH) traded down $0.03 during mid-day trading on Monday, reaching $2.21. The company’s stock had a trading volume of 467,700 shares, compared to its average volume of 340,675. Anthera Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $20.24.
Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.32. During the same period in the previous year, the business posted ($4.85) EPS. equities research analysts forecast that Anthera Pharmaceuticals will post -3.21 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-anthera-pharmaceuticals-anth-stock-price.html.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.